Wooters, T. ., Smith, A. ., Pivavarchyk, M. ., Siripurapu, K. ., McIntosh, J. ., Zhang, Z. ., … Dwoskin, L. . (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x

Horton, D. ., Siripurapu, K. ., Norrholm, S. ., Culver, J. ., Hojahmat, M. ., Beckmann, J. ., … Dwoskin, L. . (2011). meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics, 336(3), 940-51. https://doi.org/10.1124/jpet.110.175117

Beckmann, J. ., Siripurapu, K. ., , Horton, D. ., Denehy, E. ., Vartak, A. ., … Bardo, M. . (2010). The novel pyrrolidine nor-lobelane analog UKCP-110 cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics, 335(3), 841-51. https://doi.org/10.1124/jpet.110.172742

Dwoskin, L. ., Wooters, T. ., Sumithran, S. ., Siripurapu, K. ., Joyce, B. ., Lockman, P. ., … Bardo, M. . (2008). N,N’-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal of Pharmacology and Experimental Therapeutics, 326(2), 563-76. https://doi.org/10.1124/jpet.108.136630